Repligen
RGEN · NASDAQ
$178.88+$2.45 (+1.39%)TodayMarket closed ·
Prev close $176.43
About RGEN
- Employees
- 2,000
- Headquarters
- Waltham, Massachusetts
- Listed
- Apr 29, 1986
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Website
- repligen.com
Leadership
| Name | Title | Since |
|---|---|---|
| Tony Hunt | — | 2014 |
| Olivier Loeillot | — | 2023 |
| Jason Garland | — | — |
| James Bylund | — | — |
| Ralf Kuriyel | — | — |
| Karen Dawes | — | 2005 |
| Nicolas Barthelemy | — | — |
| Konstantin Konstantinov | — | — |
| Martin Madaus | — | — |
| Carrie Manner | — | — |
| Rohin Mhatre | — | — |
| Glenn Muir | — | — |
| Margaret Pax | — | — |
Revenue by product and region
Fiscal year ended Dec 31, 2019: $270.25M total revenue
By product
- Product [Member]$270.10M99.9%
- Product [Member]$270.10M99.9%
- Product [Member]$270.10M99.9%
- Filtration Products [Member]$119.53M44.2%
- Proteins Products [Member]$65.12M24.1%
- Other$85.73M31.7%
Suppliers and customers
Price correlation is over one year: 1 means the stocks move together, -1 opposite
| Company | Relationship | Correlation |
|---|---|---|
| Danaher DHR | Customer | 0.82 |
| Ecolab ECL | Customer | 0.77 |
| Merck MRK.DE | Customer | 0.63 |
| Gemini Therapeutics GMTX | Supplier and customer | 0.07 |
| Pfizer PFE | Customer | -0.08 |
| Navigo Proteins GmbH | Supplier and customer | — |
Similar companies
Companies in the same industry as Repligen
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.